Home / Market News / $AXGN

$AXGN news and market catalysts

The 20 most recent market catalysts affecting $AXGN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

20 catalysts 3 high impact 7 bullish 3 bearish Healthcare
Nov 9, 2026 Corporate Catalyst Bullish Impact 75
Axogen Reports Early Clinical Outcomes and Market Potential for Prostate Nerve Reconstruction
Axogen has released early clinical outcomes for its nerve reconstruction products in prostatectomy patients, indicating significant success with 80% reporting better-than-expected …
Oct 30, 2026 Corporate Catalyst Neutral Impact 60
Multiple Financial Institutions Update Price Targets for Axogen, Inc.
On October 30, 2026, several prominent financial institutions, including BofA Securities, Barclays, and Mizuho Securities, raised their price targets for Axogen, Inc. This broad co…
Oct 29, 2026 Corporate Catalyst Bullish Impact 65
Leerink Partners Maintains Axogen at Outperform and Raises Price Target
Leerink Partners reiterated its 'Outperform' rating for Axogen and raised its price target, indicating a positive outlook for the company. This analyst action suggests that Leerink…
Oct 29, 2026 Corporate Catalyst Bullish Impact 65
Analysts Adjust Price Targets for Axogen Following Q3 Earnings
Following Axogen's third-quarter 2026 financial results, three prominent investment banks — Truist Securities, Barclays, and Wells Fargo — have raised their price targets for the c…
Oct 28, 2026 Corporate Catalyst Neutral Impact 75
Axogen, Inc. Reports Third Quarter 2026 Financial Results
Axogen, Inc. filed an 8-K to report its third-quarter 2026 financial results, highlighting a significant 26.2% increase in revenue to $75.8 million compared to the prior year. This…
Oct 23, 2026 Corporate Catalyst Bearish Impact 55
Barclays Adjusts Axogen Price Target
Barclays has adjusted its price target for Axogen (AXGN) from $55 to $50. This change reflects a revised valuation by the analyst, potentially due to updated financial models, mark…
Oct 12, 2026 Corporate Catalyst Neutral Impact 65
B of A Securities Initiates Coverage On Axogen with Buy Rating, Announces Price Target of $52
BofA Securities analyst Travis Steed has initiated coverage on Axogen (AXGN) with a 'Buy' rating and a price target of $52. This is a significant event for Axogen as it signals a m…
Oct 1, 2026 Corporate Catalyst Bearish Impact 55
Truist Securities Maintains Buy on Axogen, Lowers Price Target to $53
Truist Securities analyst Ravi Misra maintained a 'Buy' rating on Axogen (AXGN) but lowered the price target from $60 to $53. This action signals that while the analyst still sees …
Sep 25, 2026 Corporate Catalyst Bullish Impact 60
Raymond James Maintains Outperform on Axogen, Raises Price Target to $53
Raymond James analyst Jayson Bedford maintained an 'Outperform' rating on Axogen and raised the price target from $48 to $53. This action signals increased confidence from a promin…
Sep 24, 2026 Market Technicals Neutral Impact 65
10 Health Care Stocks Whale Activity In Today’s Session
The filing details specific options trades by large investors ('whales') in various healthcare companies. This activity is significant because large-scale options trades, especiall…
Sep 10, 2026 Corporate Catalyst Neutral Impact 75
Axogen shares are trading lower. The company announced the $200 million cash acquisition of BioCircuit, and a $208.7 million public offering of common stock.
This headline represents a significant corporate catalyst for Axogen. The acquisition of BioCircuit for $200 million in cash indicates a strategic move to expand their product port…
Sep 10, 2026 Corporate Catalyst Neutral Impact 85
Axogen Prices $208.7M Underwritten Public Offering Of 4.91M Shares At $42.50 Per Share
Axogen announced the pricing of a $208.7 million underwritten public offering of 4.91 million shares at $42.50 per share. This capital raise is primarily intended to fund the acqui…
Sep 10, 2026 Corporate Catalyst Neutral Impact 92
Axogen To Acquire NerveTape Maker BioCircuit Technologies For $200M In Cash; Sees Deal As Accretive To FY27 Gross And Adjusted EBITDA Margins
Axogen is acquiring BioCircuit Technologies for $200 million in cash, funded by a public offering of common stock. This strategic acquisition brings NerveTape, a sutureless nerve r…
Aug 26, 2026 Corporate Catalyst Neutral Impact 65
Truist Securities Initiates Coverage On Axogen with Buy Rating, Announces Price Target of $60
Truist Securities analyst Ravi Misra initiated coverage on Axogen (AXGN) with a 'Buy' rating and a $60 price target. This event is significant because new analyst coverage, especia…
Jul 30, 2026 Corporate Catalyst Bullish Impact 55
Canaccord Genuity Maintains Buy on Axogen, Raises Price Target to $55
Canaccord Genuity's analyst Caitlin Roberts maintained a 'Buy' rating on Axogen and raised the price target from $50 to $55. This action signals a strengthened conviction in Axogen…
Jul 30, 2026 Corporate Catalyst Bullish Impact 55
Citizens Maintains Market Outperform on Axogen, Raises Price Target to $55
This 8-K filing discloses that Citizens analyst David Turkaly has maintained a 'Market Outperform' rating on Axogen (AXGN) and raised the price target from $50 to $55. This is a po…
Jul 30, 2026 Corporate Catalyst Bullish Impact 55
HC Wainwright & Co. Maintains Buy on Axogen, Raises Price Target to $53
HC Wainwright & Co. analyst Yi Chen has updated their coverage on Axogen, maintaining a 'Buy' rating and raising the price target from $50 to $53. This action signals a continued p…
Jul 29, 2026 Corporate Catalyst Neutral Impact 60
Axogen Participates In Series A Funding Round For Trace Biosciences With Additional Investors Expected To Join; Terms Not Disclosed
Axogen has invested in Trace Biosciences, a company developing 'Nerve Trace' technology for real-time nerve visualization during surgery. This strategic investment is significant b…
Jul 29, 2026 Corporate Catalyst Bearish Impact 92
Axogen Q2 Adj. EPS $0.12 Misses $0.13 Estimate, Sales $69.731M Beat $67.098M Estimate
Axogen's Q2 earnings report presents a mixed bag for investors. While the company demonstrated robust sales growth of over 23% year-over-year, significantly beating analyst expecta…
Jul 29, 2026 Corporate Catalyst Neutral Impact 75
Axogen FY2026 Revenue expected to be at least $279.000M vs $270.882M Est
Axogen (AXGN) has announced an upward revision to its FY2026 revenue guidance, now expecting at least $279 million, surpassing the analyst consensus of $270.882 million. This posit…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.